LABORATOIRES FORTE PHARMA S.A.M.

Shareholders of LABORATOIRES FORTE PHARMA S.A.M.

No public shareholder register entry with named shareholders or ownership percentages was located for Laboratoires Forte Pharma S.A.M. Monaco’s company registry (Répertoire du Commerce et de l’Industrie) does not routinely publish company shareholder registers, and access to the Principality’s Register of Beneficial Owners is restricted rather than publicly searchable, consistent with the on-file registry note for this company (synchronised 11 August 2026). Zavia’s on-file corporate-linkage data separately places Laboratoires Forte Pharma S.A.M. within a Spanish-headed corporate group (see Group structure), but that dataset does not itself disclose share-ownership percentages or identify a named direct shareholder, and no independent shareholder filing was retrieved during this research pass to confirm or quantify a holding.

Data availability

Shareholder and beneficial-ownership information for this Monaco-registered company is classified as Not public: the jurisdiction restricts public access to its Register of Beneficial Owners, and no shareholder register, filed-accounts note or ownership filing disclosing named shareholders or percentages for Laboratoires Forte Pharma S.A.M. could be independently verified.

Sources

On-file Zavia registry data (Répertoire du Commerce et de l’Industrie, Monaco), synchronised 11 August 2026, retrieved 17 September 2026.

Directors and officers of LABORATOIRES FORTE PHARMA S.A.M.

On-file registry data lists one active officer record for Laboratoires Forte Pharma S.A.M.: an entity named “Forte Services S.A.M.,” recorded in the Manager role, with no appointment or resignation date disclosed in the source. The name and “S.A.M.” designation indicate that this is a corporate officer — another Monégasque société anonyme acting as manager — rather than a natural person, and no jurisdiction or registration number for this corporate officer was available in the on-file data or independently located during this research pass. The officer’s recorded correspondence address is 41 Avenue Hector Otto, “Le Patio Palace,” 3rd floor, offices B3D and B3C, 98000 Monaco — the same address as the company’s own registered office — and this is treated strictly as a correspondence address, not as evidence of nationality or residence. No former or resigned officers are recorded in the on-file dataset, and no additional natural-person directors, managers or legal representatives were identified for this company in this research pass. On-file officer data was last synchronised 11 August 2026.

Data availability

Officer information for this Monaco company is classified as Partial: a single active corporate-officer record is available on file, but appointment and resignation dates, and details of any natural-person directors or legal representatives, are not disclosed in the available data. Nationality is not disclosed for the recorded officer; note also that the sole listed officer is itself a corporate entity rather than a natural person, so nationality does not apply to it.

Sources

On-file Zavia registry data (Répertoire du Commerce et de l’Industrie, Monaco), synchronised 11 August 2026, retrieved 17 September 2026.

Group structure of LABORATOIRES FORTE PHARMA S.A.M.

On-file corporate-linkage data places Laboratoires Forte Pharma S.A.M. within a Spanish-headed corporate group, synchronised 11 August 2026. Within this structure, Laboratorio Reig Jofre, S.A. (Spain, registration number ES A96184882) is recorded as the immediate parent, itself held beneath Reig Jofre Investments, S.L. (Spain, registration number ES B66115437), recorded as the ultimate parent. The same structure lists several sister companies beneath Laboratorio Reig Jofre, S.A., registered in Spain, the Czech Republic, the United Kingdom and Poland. Laboratorio Reig Jofre, S.A.’s own disclosures to Spain’s securities regulator, the Comisión Nacional del Mercado de Valores (CNMV), independently corroborate an operational link, referencing a management appointment and product launches for “Forté Pharma” as part of the group’s reported business between October 2017 and June 2018. Industry-press reports place the origin of this relationship at 31 December 2014, though that specific transaction date was not independently confirmed against a CNMV filing or annual report in this research pass. Ownership and voting percentages are not disclosed in either the on-file dataset or the CNMV disclosures reviewed.

Verified corporate relationships

Recent structural changes

Industry-press and trade reporting describe Forté Pharma as having become part of the Reig Jofre group with effect from 31 December 2014. Neither this event nor any more recent group-level transaction was independently confirmed against a CNMV filing, Monaco registry record or annual-report note during this research pass, so it is presented as reported rather than as a verified structural change.

Data availability

Corporate-linkage information for Laboratoires Forte Pharma S.A.M. is classified as Partial: an on-file dataset identifies an immediate and ultimate parent together with several sister companies by name, country and registration number, and Laboratorio Reig Jofre, S.A.’s own CNMV disclosures corroborate an operational relationship, but ownership and voting percentages are not disclosed anywhere reviewed, and the parent/subsidiary relationships have not been independently confirmed against a Monaco RCI filing, a Spanish ownership filing or a group annual-report subsidiary note in this research pass.

Sources

On-file Zavia corporate-linkage data, synchronised 11 August 2026. Laboratorio Reig Jofre, S.A. — Comunicaciones a la CNMV / Hechos relevantes, reigjofre.com, entries dated 31 October 2017, 13 November 2017, 24 January 2018 and 27 June 2018 referencing Forté Pharma, retrieved 17 September 2026. Laboratoires Forte Pharma official website, corpo.fortepharma.com, retrieved 17 September 2026.